KPIs & Operating Metrics(New)
Balance Sheet
Accounts PayablesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityConstruction in ProgressCurrent AssetsCurrent Deferred RevenueGoodwillGoodwill & IntangiblesIntangiblesLiabilities and Shareholders EquityLong-Term InvestmentsNon-Current AssetsNon-Current Deferred Tax LiabilityNon-Current Deferred Tax LiabilityNon-Current Deffered RevenueOperating LeasesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)Property, Plant & Equipment (Net)ReceivablesReceivables - NetRetained EarningsShareholder's EquityShares OutstandingShort-term InvestmentsTotal Current LiabilitiesTotal LiabilitiesTotal Non-Current LiabilitiesTreasury Shares
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

AbCellera Biologics (ABCL) Receivables (2020 - 2026)

AbCellera Biologics filings provide 7 years of Receivables readings, the most recent being $39.2 million for Q1 2026.

  • Quarterly Receivables fell 38.43% to $39.2 million in Q1 2026 from the year-ago period, while the trailing twelve-month figure was $39.2 million through Mar 2026, down 38.43% year-over-year, with the annual reading at $58.3 million for FY2025, 73.41% up from the prior year.
  • Receivables hit $39.2 million in Q1 2026 for AbCellera Biologics, down from $58.3 million in the prior quarter.
  • Across five years, Receivables topped out at $334.4 million in Q1 2022 and bottomed at $9.3 million in Q4 2022.
  • Average Receivables over 5 years is $63.2 million, with a median of $39.2 million recorded in 2026.
  • The largest annual shift saw Receivables tumbled 94.21% in 2022 before it surged 228.92% in 2023.
  • AbCellera Biologics' Receivables stood at $9.3 million in 2022, then surged by 228.92% to $30.6 million in 2023, then increased by 9.89% to $33.6 million in 2024, then soared by 73.41% to $58.3 million in 2025, then tumbled by 32.82% to $39.2 million in 2026.
  • Per Business Quant, the three most recent readings for ABCL's Receivables are $39.2 million (Q1 2026), $58.3 million (Q4 2025), and $71.2 million (Q3 2025).